tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Keen Vision Merges with Biotech Medera, Eyes NASDAQ Listing

Keen Vision Merges with Biotech Medera, Eyes NASDAQ Listing

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Keen Vision Acquisition Corporation ( (KVAC) ) has shared an announcement.

Keen Vision Acquisition Corporation (KVAC) has entered into a merger agreement with clinical-stage biotech company Medera Inc., which will result in Medera being listed on NASDAQ. The deal values Medera at approximately $622.6 million, with Medera’s founders committing $22.6 million and existing shareholders rolling 100% of their equity. The proceeds will accelerate three advanced clinical programs focused on gene therapy for heart diseases. The combined entity aims to provide innovative therapies for difficult-to-treat cardiovascular diseases, leveraging Medera’s proprietary platforms for disease modeling and drug discovery. The transaction is set to close in the fourth quarter of 2024, with Medera having a minimum of $40 million in available liquidity as a closing condition.

See more data about KVAC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1